Literature DB >> 32217447

Aspalathin-rich green Aspalathus linearis extract suppresses migration and invasion of human castration-resistant prostate cancer cells via inhibition of YAP signaling.

Shih-Han Huang1, Yung-Hsi Kao2, Christo J F Muller3, Elizabeth Joubert4, Chih-Pin Chuu5.   

Abstract

BACKGROUND: More than 80% of advanced prostate cancer (PCa) cases have bone metastasis, with a 5-year survival rate of 25%. Previously, we reported that GRT, a standardized, pharmaceutical-grade aspalathin-rich extract (12.78 g aspalathin/100 g extract), prepared from green rooibos produced from the leaves and fine stems of Aspalathus linearis, inhibits the proliferation of PCa cells, meriting this investigation to determine if GRT can suppress the migration and invasion of castration-resistant prostate cancer (CRPC) cells.
PURPOSE: In the present study, we investigated whether GRT extract can interfere with the migration and invasion of human CRPC cells.
METHODS: Transwell assays were used to explore the effects of GRT on the migration and invasion of CRPC cells. Micro-Western Array (MWA) and Western blot analysis were carried out to unravel the underlying molecular mechanism(s).
RESULTS: Treatment with 25-100 μg/ml GRT suppressed the migration and invasion of LNCaP C4-2B and 22Rv1 CRPC cells. MWA and Western blot analysis indicated that GRT treatment suppressed the protein level of yes-associated protein (YAP), macrophage stimulating 1 protein (MST1), phospho-MST1/phospho-MST2 T183/T180, and paxillin, but increased the abundance of E-cadherin. Over-expression of YAP rescued the suppressive effects of GRT on migration and invasion of CRPC cells. Treatment with the major flavonoid of GRT - the C-glucosyl dihydrochalcone, aspalathin - at a concentration of 75-100 μg/ml also reduced the migration and invasion of CRPC cells, and the inhibition was partially rescued by YAP over-expression.
CONCLUSIONS: GRT treatment suppresses the migration and invasion of CRPC cells via inhibition of YAP signaling and paxillin.
Copyright © 2020. Published by Elsevier GmbH.

Entities:  

Keywords:  Aspalathin; Invasion; Migration; Prostate cancer; Rooibos; YAP

Mesh:

Substances:

Year:  2020        PMID: 32217447     DOI: 10.1016/j.phymed.2020.153210

Source DB:  PubMed          Journal:  Phytomedicine        ISSN: 0944-7113            Impact factor:   5.340


  5 in total

Review 1.  Hibiscus, Rooibos, and Yerba Mate for Healthy Aging: A Review on the Attenuation of In Vitro and In Vivo Markers Related to Oxidative Stress, Glycoxidation, and Neurodegeneration.

Authors:  Matheus Thomaz Nogueira Silva Lima; Eric Boulanger; Frédéric J Tessier; Jacqueline Aparecida Takahashi
Journal:  Foods       Date:  2022-06-07

2.  Rooibos Flavonoids, Aspalathin, Isoorientin, and Orientin Ameliorate Antimycin A-Induced Mitochondrial Dysfunction by Improving Mitochondrial Bioenergetics in Cultured Skeletal Muscle Cells.

Authors:  Sinenhlanhla X H Mthembu; Christo J F Muller; Phiwayinkosi V Dludla; Evelyn Madoroba; Abidemi P Kappo; Sithandiwe E Mazibuko-Mbeje
Journal:  Molecules       Date:  2021-10-18       Impact factor: 4.411

3.  Aspalathus linearis suppresses cell survival and proliferation of enzalutamide-resistant prostate cancer cells via inhibition of c-Myc and stability of androgen receptor.

Authors:  Bi-Juan Wang; Shih-Han Huang; Cheng-Li Kao; Christo J F Muller; Ya-Pei Wang; Kai-Hsiung Chang; Hui-Chin Wen; Chien-Chih Yeh; Li-Jane Shih; Yung-Hsi Kao; Shu-Pin Huang; Chia-Yang Li; Chih-Pin Chuu
Journal:  PLoS One       Date:  2022-07-01       Impact factor: 3.752

Review 4.  Molecular Mechanisms of Antiproliferative Effects of Natural Chalcones.

Authors:  Radka Michalkova; Ladislav Mirossay; Maria Gazdova; Martin Kello; Jan Mojzis
Journal:  Cancers (Basel)       Date:  2021-05-31       Impact factor: 6.639

5.  Inhibition of yes-associated protein suppresses migration, invasion, and metastasis in non-small cell lung cancer in vitro and in vivo.

Authors:  Tomoya Takeda; Masanobu Tsubaki; Shuji Genno; Takuya Matsuda; Yuuta Yamamoto; Akihiro Kimura; Nao Shimizu; Shozo Nishida
Journal:  Clin Exp Med       Date:  2021-07-01       Impact factor: 3.984

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.